Pharmacogenetics in Europe: Barriers and Opportunities

  title={Pharmacogenetics in Europe: Barriers and Opportunities},
  author={David Gurwitz and Eleni Zika and Michael M. Hopkins and Sibylle Gaisser and Dolores Ibarreta},
  journal={Public Health Genomics},
  pages={134 - 141}
This paper reviews the current situation in the field of pharmacogenetics/pharmacogenomics (PGx) in Europe. High expectations surrounding the clinical application of PGx remain largely unmet, as only a limited number of such applications have actually reached the market and clinical practice. Thus, the potential impact of PGx-based diagnostics on healthcare and its socio-economic implications are still unclear. With the aim of shedding some light on these uncertainties, the Institute for… 

Tables from this paper

Clinical implementation of pharmacogenetics: a nonrepresentative explorative survey to participants of WorldPharma 2010.

The results of an explorative nonrepresentative survey are described that attempted to evaluate the perceived status quo of, and the obstacles facing, PGx implementation in clinical practice in countries with emerging and developing economies versus countries with advanced economies.

Pharmacogenomics: where does Britain stand?

PGx provides opportunities for better, more targeted treatment, treatment which reduces the incidence of adverse reactions and increases that of positive ones, and offers benefits to patients, hospitals, insurance firms and state funders of healthcare.

Are health technology assessments of pharmacogenetic tests feasible? A case study of CYP2D6 testing in the treatment of breast cancer with tamoxifen.

This paper reports the process and experience of the design and conduct of a UK-based health technology assessment (HTA) of CYP2D6 pharmacogenetic testing to inform the targeted use of tamoxifen for

Pharmacogenetic testing in the United Kingdom genetics and immunogenetics laboratories.

The range, capacity to deliver, and demand for germline pharmacogenetic testing in the United Kingdom and Ireland is established, through an e-survey of 34 molecular genetics and 28 histocompatibility and immunogenetics (H&I) laboratories.

Pharmacogenomic Testing: Clinical Evidence and Implementation Challenges

Multidisciplinary teams will need to combine their expertise to deliver optimal pharmacogenomically-informed care, as rates of genomic literacy remain low, resulting in a widening gap in knowledge translation to the patient.

Les enjeux de la translation des technologies : le cas des testsde pharmacogénétique au Québec

An exercise to provide a framework for thinking about the development of efficient translation mechanisms and the policies associated with it and to put into perspective the hopes being set forth regarding pharmacogenetics and the realistic nature of the enterprise.

Attitudes of Health Care Professionals Toward Pharmacogenetic Testing

The findings demonstrate the existence and seriousness of several challenges pertaining to pharmacogenetic applications in the clinical setting and further training and education are needed for health care professionals, since they are the ones who will most probably request these tests in the near future.

Impact of DNA patents on pharmacogenomics research and development: economic and policy issues

It is found that although recent evidence on genetic testing suggests that many of the issues in PGx might have been overestimated or overemphasized, no dedicated studies have been published on the intellectual property aspects of PGx.

Medical education in pharmacogenomics—results from a survey on pharmacogenetic knowledge in healthcare professionals within the European pharmacogenomics clinical implementation project Ubiquitous Pharmacogenomics (U-PGx)

There was a general positive attitude and interest towards pharmacogenomic testing, however, the grade of own experience, and knowledge about application and interpretation of pharmacogenomics caused uncertainty, so education and training programmes may be helpful for implementation of Pharmacogenomics at a homogenous level within Europe.



Priorities and standards in pharmacogenetic research

As the attention of researchers begins to shift toward more systematic pharmacogenetic investigations, it is suggested some priorities and standards for pharmacogenetics research.

Economic Advantage of Pharmacogenomics - Clinical Trials with Genetic Information

This study shows that the advantage of pgx clinical trial outweighs its disadvantage, and the number of subjects necessary for a clinical trial can be reduced, study period can be shortened and the drug can be marketed earlier.

From pharmacogenetics to personalized medicine: a vital need for educating health professionals and the community.

To effectively move pharmacogenetics into everyday medicine, it is imperative for scientists and teachers in the field to take on the challenge of disseminating pharmacogenetic insights to a broader audience.

Clinical genomics data standards for pharmacogenetics and pharmacogenomics.

  • A. Shabo
  • Computer Science
  • 2006
This special report concerns a talk on data standards given at a workshop entitled 'An International Perspective on Pharmacogenetics: The Intersections between Innovation, Regulation and Health

Avoiding adverse drug reactions by pharmacogenetic testing: A systematic review of the economic evidence in the case of TPMT and AZA-induced side effects

Solid economic considerations related to TPMT pharmacogenetic testing are still limited by underreporting of ADRs and high level of approximation related to cost data.

Pharmacogenetics and pharmacogenomics: development, science, and translation.

Significant challenges remain to be overcome if pharmacogenetics-pharmacogenomics is to achieve its full potential as a major medical application of genomic science.

Translating Pharmacogenomics: Challenges on the Road to the Clinic

This article presents specific clinical examples of such challenges and discusses how obstacles to implementation of pharmacogenomic testing can be addressed and how the application in patient care remains very limited.

Building effective institutional frameworks to support pharmacogenetic research: an international empirical analysis

The objective of this paper is to analyse the current state of PGx research and explore future strategies for more efficient research projects and supportive infrastructures.

Pharmacogenomics: Challenges and Opportunities

This review will outline progress in the field by describing mechanisms underlying variable drug responses, the potential role of genetic factors in their causes, and contemporary and evolving approaches to identifying these genetic factors.

Pharmacogenetics, ethical issues: review of the Nuffield Council on Bioethics Report

The extent to which the Nuffield Council on Bioethics report was successful in addressing (or at least highlighting) the attendant social, ethical, and policy implications of pharmacogenetics research is evaluated.